X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Bought by State Street Corp

State Street Corp lifted its stake in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 6.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,952,895 shares of the company’s stock after buying an additional 189,105 shares during the period. State Street Corp’s holdings in X4 Pharmaceuticals were worth $1,976,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Verition Fund Management LLC acquired a new position in X4 Pharmaceuticals during the 3rd quarter worth approximately $30,000. SG Americas Securities LLC purchased a new stake in shares of X4 Pharmaceuticals during the third quarter valued at approximately $37,000. XTX Topco Ltd acquired a new position in shares of X4 Pharmaceuticals during the second quarter worth $65,000. Rhumbline Advisers boosted its stake in shares of X4 Pharmaceuticals by 14.6% in the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after purchasing an additional 23,831 shares during the period. Finally, AQR Capital Management LLC grew its holdings in X4 Pharmaceuticals by 1,080.3% during the 2nd quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock valued at $246,000 after purchasing an additional 388,115 shares in the last quarter. Institutional investors and hedge funds own 72.03% of the company’s stock.

Insider Transactions at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 230,645 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $0.55, for a total transaction of $126,854.75. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Mary Dibiase sold 67,695 shares of X4 Pharmaceuticals stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $0.57, for a total value of $38,586.15. Following the completion of the transaction, the chief operating officer now owns 452,060 shares of the company’s stock, valued at approximately $257,674.20. The trade was a 13.02 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 580,800 shares of company stock valued at $321,447. Insiders own 1.62% of the company’s stock.

Analysts Set New Price Targets

XFOR has been the subject of a number of analyst reports. Stifel Nicolaus decreased their price objective on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. HC Wainwright reduced their price target on X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating for the company in a report on Thursday, November 14th.

X4 Pharmaceuticals Stock Down 9.2 %

Shares of NASDAQ:XFOR opened at $0.73 on Thursday. X4 Pharmaceuticals, Inc. has a 12-month low of $0.26 and a 12-month high of $1.60. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. The firm has a market cap of $125.11 million, a PE ratio of -8.15 and a beta of 0.35. The company has a fifty day simple moving average of $0.53 and a 200 day simple moving average of $0.63.

X4 Pharmaceuticals Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.